Use of Al18F-PSMA-BCH PETCT Scan for Detecting Tumors Expressing Prostate Specific Membrane Antigen Including Various Cancers

What this Trial Is About

This research aims to evaluate the effectiveness of Al18F-PSMA-BCH PETCT imaging in detecting tumors that express prostate specific membrane antigen PSMA. The study focuses on patients with suspected or confirmed PSMA-positive tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, and multiple myeloma. It is a phase 2 interventional trial sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Participants will receive an intravenous injection of Al18F-PSMA-BCH followed by a PETCT scan to assess tumor presence. This imaging procedure is the main intervention being studied, aiming to evaluate its tumor detection ability. The study does not include a comparison group or placebo, and there is no masking or blinding involved. During the study, participants will undergo the PETCT scan after the tracer injection, and researchers will measure the diagnostic value of the imaging over approximately one year. Participants must be willing to cooperate with all study procedures and provide informed consent. Safety and diagnostic outcomes will be monitored throughout the study period, which is expected to complete by October 2025.

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor